SEC 13F Intelligence

Managers / Q4 2018 · view latest →

TANG CAPITAL MANAGEMENT LLC

CIK 0001232621 · 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO, CA, 92121 · 858-200-3830

Reported Value
$436M
Q4 2018
Positions
10
Filings on Record
30
2019–present window
Filed
Feb 14, 2019
original filing

Summary

Tang Capital Management LLC reported $436M in U.S.-listed holdings across 10 positions for Q4 2018.

The portfolio is heavily concentrated: Odonate Therapeutics alone accounts for 45.4% of reported value.

Portfolio Metrics

Top-10 Concentration
+100.0%
share of reported value
Largest Position
+45.4%
Odonate Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $436MQ4 ’18Q1 ’19: $543MQ2 ’19: $740MQ3 ’19: $584MQ4 ’19: $837MQ4 ’19Q1 ’20: $712MQ2 ’20: $1.0BQ3 ’20: $553MQ4 ’20: $655MQ4 ’20Q1 ’21: $355MQ2 ’21: $502MQ3 ’21: $482MQ4 ’21: $497MQ4 ’21Q1 ’22: $500MQ2 ’22: $659MQ3 ’22: $815MQ4 ’22: $688MQ4 ’22Q1 ’23: $671MQ2 ’23: $679MQ3 ’23: $709MQ4 ’23: $1.1BQ4 ’23Q1 ’24: $960MQ2 ’24: $982MQ3 ’24: $1.4BQ4 ’24: $1.5BQ4 ’24Q1 ’25: $1.8BQ2 ’25: $2.0BQ3 ’25: $2.6BQ4 ’25: $2.0BQ4 ’25Q1 ’26: $2.0Bfilingsflow.com

Portfolio Composition

By security type
Common Stock: 54.3%Other: 45.7%
  • Common Stock · 54.3% · $237M
  • Other · 45.7% · $199M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ODONATE THERAPEUTICS INCNEW+14.05M14.05M+$198M$198M
AXD2HERON THERAPEUTICS INCNEW+5.82M5.82M+$151M$151M
RCKTROCKET PHARMACEUTICALS INCNEW+2.97M2.97M+$44M$44M
LJPCLA JOLLA PHARMACEUTICAL CONEW+3.88M3.88M+$37M$37M
PBYIPUMA BIOTECHNOLOGY INCNEW+247.4K247.4K+$5M$5M
OPHTHOTECH CORPNEW+600.0K600.0K+$720,000$720,000
PROTHENA CORP PLCNEW+47.6K47.6K+$490,000$490,000
EQEQUILLIUM INCNEW+47.3K47.3K+$386,000$386,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

8 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ODONATE THERAPEUTICS INCCOM45.38%$198M14.05M
2AXD2HERON THERAPEUTICS INChistory →COM34.63%$151M5.82M
3RCKTROCKET PHARMACEUTICALS INChistory →COM10.08%$44M2.97M
4LJPCLA JOLLA PHARMACEUTICAL COhistory →COM8.39%$37M3.88M
5PBYIPUMA BIOTECHNOLOGY INChistory →COM1.16%$5M247.4K
6OPHTHOTECH CORPCOM0.17%$720,000600.0K
7PROTHENA CORP PLCSHS0.11%$490,00047.6K
8EQEQUILLIUM INCCOM0.09%$386,00047.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$2.0B51May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$2.0B75Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$2.6B194Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$2.0B200Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$1.8B202May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.5B183Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$1.4B154Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$982M128Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$960M99May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$1.1B123Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$709M106Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$679M99Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$671M103May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$688M89Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$815M95Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$659M67Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$500M53May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$497M29Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$482M20Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$502M16Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$355M11May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$655M11Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$553M20Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.0B21Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$712M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$837M17Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$584M12Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$740M10Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$543M9May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$436M10Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • TANG KEVIN C028-14818

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.